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Activation of the adrenergic system has a profound effects on metabolism. Increased
circulating catecholamine and activation of the different adrenergic receptors deployed in
the various organs produce important metabolic responses which include: (1) increased
lipolysis and elevated levels of fatty acids in plasma, (2) increased gluconeogenesis
by the liver to provide substrate for the brain, and (3) moderate inhibition of insulin
release by the pancreas to conserve glucose and to shift fuel metabolism of muscle
in the direction of fatty acid oxidation. These physiological responses, typical of the
stress conditions, are demonstrated to be detrimental for the functioning of different
organs like the cardiac muscle when they become chronic. Indeed, a common feature
of many pathological conditions involving over-activation of the adrenergic system is the
development of metabolic alterations which can include insulin resistance, altered glucose
and lipid metabolism and mitochondrial dysfunction. These patterns are involved with
a variably extent among the different pathologies, however, they are in general strictly
correlated to the level of activation of the adrenergic system. Here we will review the
effects of the different adrenergic receptors subtypes on the metabolic variation observed
in important disease like Heart Failure.
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INTRODUCTION
Heart function relies to a great extent on cardiac muscle oxida-
tive metabolism. Given the high mitochondrial content of this
tissue, cardiac muscle generates ATP almost exclusively (about
90%) through oxidative phosphorylation (Stanley et al., 2005)
by using different metabolic substrates. Indeed, cardiac muscle
possesses a metabolic flexibility or plasticity, allowing it to main-
tain its function during stressful conditions. In the adult heart
the major pathway for ATP production is fatty acid oxidation
while the relative contribution of glucose increases during stress
or injury, such as exercise or ischemia (Bing et al., 1954; Wisneski
et al., 1987). Thus, it is not surprising that an impairment of
cardiac muscle energy metabolism represents an important risk
factor for the development of cardiac diseases (Stanley et al.,
2005; Neubauer, 2007). Indeed, under pathological conditions,
the heart exhibits a severe malfunction of different metabolic
pathways, such as the tricarboxylic acid (TCA) cycle and b-
oxidation (Stanley et al., 2005; Neubauer, 2007). This metabolic
remodeling is characterized by a lower oxidative capacity, con-
tractile dysfunction and cardiac muscle insulin resistance (Stanley
et al., 2005; Neubauer, 2007). Different therapeutic strategies
have been undertaken to modulate metabolic pathways in the
failing heart, though it remains controversial whether targeting
glucose vs. fatty acid metabolism individually or combined rep-
resents a better approach to improve metabolic flexibility and
cardiac function (Kolwicz and Tian, 2009; Ardehali et al., 2012).
Surely, the importance of a preserved metabolism includes not
only an efficient energy supply needed for myocardium to accom-
plish his contractile function but also protection against oxidative
stress (Neubauer, 2007), which is involved in the remodeling and
progression of the disease.
CARDIAC METABOLIC DYSFUNCTION DURING HF
Animal models of HF have evidenced excessive uptake and
myocardial free fatty acid (FFA) accumulation with reduced glu-
cose utilization (Lommi et al., 1998; Taylor et al., 2001) and in
both animal models of HF and in human disease these metabolic
alterations reduce myocardial oxygen efficiency and lead to a
depletion of intracellular ATP (Neubauer et al., 1992; Taylor et al.,
2001). The importance of a preserved glucose cardiac utilization
may be related to its higher efficiency in terms of ATP pro-
duction and molecule of oxygen consumed, with consequently
reduced oxygen wastage and reactive oxygen species (ROS) pro-
duction, as compared to FFA. Insulin receptor signaling is crit-
ically involved in increasing glucose uptake in the myocardium
and cardiac insulin resistance contributes to the development of
left ventricular (LV) dysfunction by reducing cardiac efficiency
through metabolic shift toward fatty acids utilization (Peterson
et al., 2004b). Indeed, a profound state of insulin resistance has
been found in the hearts of ob/ob mice and the ability of these
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hearts to modulate substrate utilization in response to insulin and
changes is altered (Mazumder et al., 2004). Accordingly, normal-
ization of cardiac metabolism by overexpressing a human GLUT4
transgene in mice with cardiac insulin resistance recovered the
altered cardiac function observed in these animals (Belke et al.,
2000; Semeniuk et al., 2002). Therefore, these studies indicate
that cardiac insulin resistance reduces the metabolic efficiency
of the heart, which leads to a contractile dysfunction. Moreover,
insulin resistance is a known and recognized phenomenon lead-
ing to HF (Boudina et al., 2009) as seen in positron emis-
sion tomographic (PET) studies showing that the failing human
myocardium has reduced glucose uptake in favor of FFA uptake
(Witteles et al., 2004). Several hypotheses have been proposed
to explain the association between altered cardiac metabolism,
insulin resistance, and HF, and among these there is a strong
correlation with neurohormonal activation (Kostis and Sanders,
2005; Zucker, 2006), which increases plasma FFA levels, inhibits
insulin receptor signaling and causes the loss of myocyte glucose
uptake (Opie and Sack, 2002). As known neurohormonal activa-
tion includes over-activation of the adrenergic and RAAS system,
and we will here specifically focus on the adrenergic mecha-
nisms that underlie altered myocardial metabolism and insulin
resistance in HF.
SYMPATHETIC NERVOUS SYSTEM AND CARDIAC METABOLISM: ROLE
OF THE β ADRENERGIC RECEPTORS AND RELATED SIGNALING
The Sympathetic Nervous System (SNS) is maladaptively acti-
vated in response to a chronic reduction in cardiac output and
it is characterized by an increased secretion and reduced cardiac
catecholamine reuptake (Eisenhofer et al., 1996). The effects of
the catecholamine incretion on the cardiac metabolism are medi-
ated by both central and peripheral mechanisms. For example,
increased catecholamines have directly detrimental effects on the
heart, which cause marked enzyme loss as an index of diffuse
myocardial damage, and substantial oxygen-wastage even in the
absence of FFA in the perfusate (Opie et al., 1979). Furthermore,
norepinephrine promotes both coronary vasoconstriction and
increased plasma FFA levels (Paolisso et al., 1991), which further
promote oxygen-wastage (Sasaoka et al., 2006). Infusion studies
in volunteers support a role for increased norepinephrine levels
in HF as a cause of elevated plasma FFA (Sasaoka et al., 2006). In
turn, FFAs reciprocally augment SNS activity, at least in normal
controls. In human skeletal muscle, a dose-response relationship
exists between plasma FFA (Santomauro et al., 1999; Peterson
et al., 2004a; Banerjee and Peterson, 2007) and defects in insulin
signaling (Belfort et al., 2005). This may in part be caused by FFA-
mediated activation of protein kinase C, which phosphorylates
insulin receptors and results in reduced capillary opening and
reduced myocyte glucose import (Itani et al., 2002; Wagenmakers
et al., 2006). Moreover, also locally activated SNS appear to be rel-
evant in the altered cardiac metabolism. With use of PET with a
norepinephrine analog and 18F-fluorodeoxyglucose, myocardial
segments with LV dysfunction have reduced presynaptic nore-
pinephrine reuptake and myocardial glucose uptake in relation to
less impairedmyocardial segments in the same patients (Mongillo
et al., 2007). Thus, after control for confounding variables, altered
metabolism and IR directly relate to local SNS activity. As known,
the adverse effects of the SNS on the heart are mediated by the
adrenergic receptors (AR), however, extensive research has indi-
cated that the various subtypes, in particular β1 and β2 ARs,
are differently involved in pathophysiology of HF and so it is
likely to be the same for modifications of cardiac metabolism
observed during disease. Indeed, β1- and β2-AR regulate differ-
ent signal pathways, resulting in different outcomes on cardiac
function. Stimulation of β1- and β2-adrenoceptors can induce
the activation of the stimulatory G protein (Gαs)/adenylylcyclase
(AC)/cAMP/cAMP-dependent protein kinase A (PKA) signal-
ing pathway, which consequently leads to the phosphorylation
of several target proteins within the cardiac myocyte, such as
phospholamban, L-type calcium channel and troponin I (Woo
and Xiao, 2012). Nonetheless, this signal pathway is the main
mechanism by which β1- rather than β2 adrenoceptors regulates
cardiac contractility/relaxation and rate (Baruscotti et al., 2010;
Woo and Xiao, 2012). In contrast, the β2 AR has been shown to
regulate an alternative signaling pathway through activation of
the inhibitory G protein (Gαi) and the heterodimer formed by
the β and γ subunits of the G protein (Gβγ) (Zhu et al., 2011).
Besides the inhibition of AC, themain signal pathway regulated by
β2-AR through Gαi/Gβγ appears to be the phosphatidylinositol-
3kinase (PI3K) signaling cascade, although other proteins such
as the AMP-dependent protein kinase (AMPK), mammalian
target of rapamycin (mTOR) and extracellular signal-regulated
kinase1and 2 (ERK1/2) have recently been proposed as novel
targets of β2-AR (Zhang et al., 2011). About the effects of adren-
ergic system on metabolism, it is known that sustained beta
adrenergic stimulation induce insulin resistance (Cipolletta et al.,
2009) and in this context the β2 adrenergic receptor appears
to have a main role in overall glucose homeostasis by acting
on pancreatic islet hormone secretion, liver and muscle glucose
transport metabolism (Usui et al., 2005; Shahid and Hussain,
2007; Garcia-Guerra et al., 2010). At cardiac level several studies
have raised the possibility of using selective β2-agonists as poten-
tial modulators of cardiac muscle energy metabolism. Short- and
long-term stimulation of the β2-AR has been associated with
the modulation of fatty acid and glucose metabolism (Philipson,
2002). Indeed, acute treatment of myocytes in vitro or skeletal
muscle ex vivo with β2 agonists induces a significant increase
in glucose uptake, reaching comparable levels to insulin stim-
ulation (Nevzorova et al., 2002, 2006; Ngala et al., 2008). A
putative mechanism for these evidence would involve the acti-
vation of PI3K and its downstream signal pathway (Zhu et al.,
2001; Jo et al., 2002; Perez-Schindler et al., 2011; Zhang et al.,
2011) and in particular the phosphorylation and inactivation
of TBC1D4 (also known as Akt substrate of 160 kDa, AS160)
by Akt (Sakamoto and Holman, 2008). TBC1D4 inhibit the
translocation of the glucose transporter type4 (GLUT4) from
intracellular vesicles to the plasmamembrane, hence an increase
in TBC1D4 phosphorylation would consequently enhance glu-
cose uptake (Sakamoto and Holman, 2008). Moreover, TBC1D4
is also targeted by AMPK, which represent a keymechanism in the
regulation of insulin-independent glucose uptake (Sakamoto and
Holman, 2008;Maarbjerg et al., 2011). Consistent with the poten-
tial role of β2-AR in glucose metabolism, high levels of AMPK
phosphorylation and activity in response to β2-AR stimulation
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FIGURE 1 | (A) In basal or low stimulation conditions GRK2 is mostly
cytosolic and its level are tightly regulated by mdm2 ubiquitination and
degradation through the Proteasome. (B) Following acute or excessive
stimulation by catecholamines or Insulin or hypoxia, GRK2 detaches from
mdm2 and quickly accumulates in the cell, moving to membranes where
desensitizes β-AR and IR. Moreover, it can translocates to the mitochondria,
reducing ATP loss and inducing mitochondria biogenesis (β-AR, β Adrenergic
Receptor; IR, Insulin Receptor; CA, Catecholamine; I, Insulin).
(Li et al., 2010; Perez-Schindler et al., 2011) have been found
in cardiomyocytes, potentially as consequence of an increase in
the AMP/ATP ratio, or activation of upstream AMPK kinases
(Hardie et al., 2012). Different results, however, have been found
in presence of an enhanced β2-AR signaling by means of sta-
ble overexpression in non-cardiac cells, where, in vitro studies
shows impaired glucose extraction later on insulin stimulation
(Cipolletta et al., 2009). Moreover “in vivo” studies demonstrated
a greater efficiency of carvedilol, a non-selective β-AR antagonist,
in ameliorating myocardial insulin sensitivity and glucose extrac-
tion in animal model of HF as compared tometoprolol, a selective
β1-AR antagonist, indicating that antagonism of β2AR positively
regulates cardiac glucose metabolism in an animal model HF
(Nikolaidis et al., 2006). These conflicting results may rely on
the different models used for studies and/or to differences in
acute and chronic stimulation of the β2AR. While acute activa-
tion of the receptor can favor glucose uptake by increasing GLUT4
translocation to the plasmamembrane, chronic adrenergic stim-
ulation, as seen during HF, would be rather detrimental by up or
down regulation of specific intracellular molecules. Recent dis-
coveries have found in the kinase of the G protein coupled recep-
tor type 2 (GRK2) a potential molecular link between chronic
adrenergic stimulation and development of altered myocardial
metabolism observed during HF (Ciccarelli et al., 2011). So far,
the implications of GRK2 upregulation during HF have been
exclusively considered for the detrimental effects on βAR signal-
ing and cardiac inotropism (Koch et al., 1995), however, studies
in non-cardiac cells have shown ability to interact with different
substrates belonging to different cellular pathways such as insulin
signaling, and, of note, to mediate insulin resistance produced by
enhanced β2-AR receptor signaling (Cipolletta et al., 2009). In
the failing heart GRK2 is upregulated (Iaccarino et al., 2005) and
affects myocardial glucose uptake at the early stages of the disease,
before cardiac dilation and reduced function are evident, indicat-
ing that metabolic modifications are relevant in the progression
of HF and to be the molecular link between over-activation of
the adrenergic system and the altered glucose uptake during HF
(Ciccarelli et al., 2011). Recent studies have also indicated that
GRK2 is also able to localize into mitochondria, but this role in
the global cellular physiology is not completely clear. Indeed, dif-
ferent cellular models have shown different behaviors of GRK2
when it localizes into mitochondria. Specifically, Fusco et al.
have indicated that GRK2 is protective for the cell by increasing
ATP production and promoting mitogenesis (Fusco et al., 2012).
As known, GRK2 shuttles from cytosol to plasmamembrane,
by anchoring to free Gβγ through its pleckstrin homology and
binding domains within the carboxyl terminus, following both
catecholamine and insulin stimulation. Similarly, ischemia causes
acute cellular and mitochondrial accumulation of GRK2 (Fusco
et al., 2012), an effect reverted by oxygen restoration, but, surpris-
ingly it preserves ATP loss and induces mitochondria biogenesis
after ischemia/reperfusion, indicating a protective effect of GRK2
for mitochondria after acute stress.
These data are supported by the importance of GRK2 for
embryonic cardiac development (Jaber et al., 1996) and, in adult
life, by the early eccentric dilation of the heart and the vas-
cular inflammation induced by selective GRK2 removal in the
myocardium and endothelium, respectively (Brunn et al., 2006;
Ciccarelli et al., 2013). On the contrary, Chen et al. have also
shown that elevated level of GRK2 activates a pro-death signal
through its localization into mitochondria during stress condi-
tions (Chen et al., 2013).
This discrepancy could be related to the model and timing
used in different studies, however, in a synthetic view of the latest
GRK2 studies, we could advance the idea that the inhibitory prop-
erty of GRK2 could be useful in acute phase of stress/stimulation,
when the cytosolic molecule shuttles to the plasmamembrane
and mitochondria, setting cellular activity in a resting phase
and less susceptible to the stress and/or excess of signaling.
However, in a perpetuating situation, the increased activity/level
of GRK2 and chronic reduction of β adrenergic and insulin
signaling becomes detrimental for cell function and survival
(Figures 1A,B). Further studies will be needed to evaluate this
hypothesis; nevertheless, several reports already indicate GRK2 as
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a potential target for treatment of both altered metabolism and
contractility during HF.
CONCLUSIONS AND PERSPECTIVES
Modification of cardiac metabolism is a fascinating field of inves-
tigation for development of new strategies for treatment of
myocardial dysfunction. This consideration is based on the evi-
dence that an efficient metabolic supply is needed for the single
cardiomyocyte to accomplish its contractile function and efficient
utilization is also important to counteract oxygen wastage and
increased ROS on which relies progression of the disease. Current
available compounds acting on the βARs seem to be effective for
these goals, however, identification of specific target, as GRK2,
clearly involved in regulation of cardiac contractility, remodeling
and metabolism would prepare the ground for a more efficient
therapy aimed to ameliorate patients prognosis and outcome.
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